TY - JOUR
T1 - Mild intermittent hypoxia exposure induces metabolic and molecular adaptations in men with obesity
AU - van Meijel, R.L.J.
AU - Vogel, M.A.A.
AU - Jocken, J.W.E.
AU - Vliex, L.M.M.
AU - Smeets, J.S.J.
AU - Hoebers, N.
AU - Hoeks, J.
AU - Essers, Y.
AU - Schoffelen, P.F.M.
AU - Sell, H.
AU - Kersten, S.
AU - Rouschop, K.M.A.
AU - Blaak, E.E.
AU - Goossens, G.H.
N1 - Funding Information:
This study was supported by a Senior Fellowship grant from the Dutch Diabetes Research Foundation (grant number: 2015.82.1818 ) and a Rising Star Award Fellowship (2014) from the European Foundation for the Study of Diabetes to G.G.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Objective: Recent studies suggest that hypoxia exposure may improve glucose homeostasis, but well-controlled human studies are lacking. We hypothesized that mild intermittent hypoxia (MIH) exposure decreases tissue oxygen partial pressure (pO2) and induces metabolic improvements in people who are overweight/obese. Methods: In a randomized, controlled, single-blind crossover study, 12 men who were overweight/obese were exposed to MIH (15 % O2, 3 x 2 h/day) or normoxia (21 % O2) for 7 consecutive days. Adipose tissue (AT) and skeletal muscle (SM) pO2, fasting/postprandial substrate metabolism, tissue-specific insulin sensitivity, SM oxidative capacity, and AT and SM gene/protein expression were determined. Furthermore, primary human myotubes and adipocytes were exposed to oxygen levels mimicking the hypoxic and normoxic AT and SM microenvironments. Results: MIH decreased systemic oxygen saturation (92.0 +/- 0.5 % vs 97.1 +/- 0.3, p < 0.001, respectively), AT pO2 (21.0 +/- 2.3 vs 36.5 +/- 1.5 mmHg, p < 0.001, respectively), and SM pO2 (9.5 +/- 2.2 vs 15.4 +/- 2.4 mmHg, p = 0.002, respectively) compared to normoxia. In addition, MIH increased glycolytic metabolism compared to normoxia, reflected by enhanced fasting and postprandial carbohydrate oxidation (pAUC = 0.002) and elevated plasma lactate concentrations (pAUC = 0.005). Mechanistically, hypoxia exposure increased insulin-independent glucose uptake compared to standard laboratory conditions (-50 %, p < 0.001) and physiological normoxia (-25 %, p = 0.019) through AMP-activated protein kinase in primary human myotubes but not in primary human adipocytes. MIH upregulated inflammatory/metabolic pathways and downregulated extracellular matrix-related pathways in AT but did not alter systemic inflammatory markers and SM oxidative capacity. MIH exposure did not induce significant alterations in AT (p = 0.120), hepatic (p = 0.132) and SM (p = 0.722) insulin sensitivity. Conclusions: Our findings demonstrate for the first time that 7-day MIH reduces AT and SM pO2, evokes a shift toward glycolytic metabolism, and induces adaptations in AT and SM but does not induce alterations in tissue-specific insulin sensitivity in men who are overweight/obese. Future studies are needed to investigate further whether oxygen signaling is a promising target to mitigate metabolic complications in obesity. Clinical trial registration: This study is registered at the Netherlands Trial Register (NL7120/NTR7325). (c) 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
AB - Objective: Recent studies suggest that hypoxia exposure may improve glucose homeostasis, but well-controlled human studies are lacking. We hypothesized that mild intermittent hypoxia (MIH) exposure decreases tissue oxygen partial pressure (pO2) and induces metabolic improvements in people who are overweight/obese. Methods: In a randomized, controlled, single-blind crossover study, 12 men who were overweight/obese were exposed to MIH (15 % O2, 3 x 2 h/day) or normoxia (21 % O2) for 7 consecutive days. Adipose tissue (AT) and skeletal muscle (SM) pO2, fasting/postprandial substrate metabolism, tissue-specific insulin sensitivity, SM oxidative capacity, and AT and SM gene/protein expression were determined. Furthermore, primary human myotubes and adipocytes were exposed to oxygen levels mimicking the hypoxic and normoxic AT and SM microenvironments. Results: MIH decreased systemic oxygen saturation (92.0 +/- 0.5 % vs 97.1 +/- 0.3, p < 0.001, respectively), AT pO2 (21.0 +/- 2.3 vs 36.5 +/- 1.5 mmHg, p < 0.001, respectively), and SM pO2 (9.5 +/- 2.2 vs 15.4 +/- 2.4 mmHg, p = 0.002, respectively) compared to normoxia. In addition, MIH increased glycolytic metabolism compared to normoxia, reflected by enhanced fasting and postprandial carbohydrate oxidation (pAUC = 0.002) and elevated plasma lactate concentrations (pAUC = 0.005). Mechanistically, hypoxia exposure increased insulin-independent glucose uptake compared to standard laboratory conditions (-50 %, p < 0.001) and physiological normoxia (-25 %, p = 0.019) through AMP-activated protein kinase in primary human myotubes but not in primary human adipocytes. MIH upregulated inflammatory/metabolic pathways and downregulated extracellular matrix-related pathways in AT but did not alter systemic inflammatory markers and SM oxidative capacity. MIH exposure did not induce significant alterations in AT (p = 0.120), hepatic (p = 0.132) and SM (p = 0.722) insulin sensitivity. Conclusions: Our findings demonstrate for the first time that 7-day MIH reduces AT and SM pO2, evokes a shift toward glycolytic metabolism, and induces adaptations in AT and SM but does not induce alterations in tissue-specific insulin sensitivity in men who are overweight/obese. Future studies are needed to investigate further whether oxygen signaling is a promising target to mitigate metabolic complications in obesity. Clinical trial registration: This study is registered at the Netherlands Trial Register (NL7120/NTR7325). (c) 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
KW - Hypoxia exposure
KW - Obesity
KW - Insulin sensitivity
KW - Substrate metabolism
KW - Inflammation
KW - RCT
KW - TISSUE OXYGEN-TENSION
KW - INSULIN SENSITIVITY
KW - GLUCOSE-TOLERANCE
KW - SKELETAL-MUSCLE
KW - RESVERATROL SUPPLEMENTATION
KW - OXIDATION
KW - TRANSCRIPTION
KW - MACROPHAGES
KW - EXPRESSION
KW - RESISTANCE
U2 - 10.1016/j.molmet.2021.101287
DO - 10.1016/j.molmet.2021.101287
M3 - Article
C2 - 34224918
SN - 2212-8778
VL - 53
JO - Molecular Metabolism
JF - Molecular Metabolism
M1 - 101287
ER -